United Therapeutics (NASDAQ:UTHR) CEO Sells $1,753,200.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $438.30, for a total transaction of $1,753,200.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $56,979. The trade was a 96.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Price Performance

Shares of UTHR opened at $454.00 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $479.50. The stock has a fifty day moving average price of $421.07 and a 200 day moving average price of $342.41. The company has a market cap of $19.55 billion, a P/E ratio of 17.20, a PEG ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the business earned $6.39 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on UTHR shares. Oppenheimer raised their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. HC Wainwright increased their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Bank of America lifted their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Wells Fargo & Company upped their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Finally, Royal Bank Of Canada increased their price target on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $503.90.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB raised its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares in the last quarter. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth $29,000. Abich Financial Wealth Management LLC bought a new position in shares of United Therapeutics during the 3rd quarter valued at $44,000. SVB Wealth LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at $32,000. Finally, WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.